IVIG is an FDA-Approved medication. It has been prescribed off-label for Alzheimer’s. Despite recent failures in clinical trials, pharmaceutical companies and academic institutions are convinced of its potential as a new dementia treatment. They continue to invest in finding ways it can improve Alzheimer’s. Learn the latest about this experimental Alzheimer’s treatment.
Dr. Maria Carrillo of the Alzheimer’s Association gives “big picture” perspective on the IVIG Phase 3 results at AAIC 2013.
